- Bevacizumab is associated with better progression and survival outcomes in primary tumor-unresected and primary tumor-resected metastatic colorectal cancer (mCRC).
- These authors find the results for resected tumor more convincing.
Why this matters
- The study is the first meta-analysis to examine the association between primary tumor resection and survival among patients with mCRC treated with bevacizumab.
- A meta-analysis of 7 studies (N=2760).
- Funding: National Natural Science Fund of China; Natural Science Fund of Hubei Province.
- Compared with patients whose primary tumor was not resected, patients whose primary tumor was resected (6 studies) had better:
- OS: HR, 0.50 (P<.00001>
- PFS: HR, 0.65 (P=.0002).
- OS (3 studies): HR, 0.65 (P<.00001>
- PFS (2 studies): HR, 0.68 (P=.0001).
- OS: HR, 0.78 (P=.009).
- PFS: HR, 0.71 (P=.002).
- However, the significant OS benefit depended on results from a single study.
- 5 studies were retrospective, 2 prospective.